{"type":"trials","record":{"id":41397,"source_id":"clinicaltrials-gov","external_id":"NCT05769153","title":"Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)","brief_summary":"The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).","overall_status":"Active Not Recruiting","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Alcon Research","enrollment":139,"countries":["United States"],"start_date":"2023-12-06","completion_date":"2027-09-01","last_update_date":"2026-08-27","source_url":"https://clinicaltrials.gov/study/NCT05769153","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"NOVA-1","age_range":"50 Years","comparator":"Aflibercept (Stage 2)","organization":"Alcon Research","interventions":["AR-14034 SR implant lower dose","AR-14034 SR implant higher dose","AR-14034 SR implant","Aflibercept Injection","Sham procedure"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change from baseline in ETDRS BCVA at the average across two visits, Weeks 44 and 48 (Stage 2) — Baseline, Week 44…","Mean change from baseline in ETDRS BCVA by visit (Stage 2) — Baseline to Week 56","Mean change from baseline in Central Subfield Thickness (CST) by visit (Stage 2) — Baseline to Week 56"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration (nAMD)","AR-14034 SR implant lower dose","AR-14034 SR implant higher dose","AR-14034 SR implant","Aflibercept Injection","Sham procedure"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05769153","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-12-06 to 2027-09-01","comparator":"Aflibercept (Stage 2)","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.805Z","intervention":["AR-14034 SR implant lower dose","AR-14034 SR implant higher dose","AR-14034 SR implant","Aflibercept Injection","Sham procedure"],"participants":139,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change from baseline in ETDRS BCVA at the average across two visits, Weeks 44 and 48 (Stage 2) — Baseline, Week 44…","Mean change from baseline in ETDRS BCVA by visit (Stage 2) — Baseline to Week 56","Mean change from baseline in Central Subfield Thickness (CST) by visit (Stage 2) — Baseline to Week 56"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41397","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}